News

Coherus Oncology to Present Innovative Cancer Research at SITC

Coherus Oncology to Present Innovative Cancer Research at SITC

Coherus Oncology's Groundbreaking Presentation at SITC

Coherus Oncology, Inc. (NASDAQ: CHRS), recognized for its commitment to advancing cancer treatment, has exciting news! An engaging poster presentation is scheduled for the upcoming 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) from November 5 to 9, 2025. This event promises to be a significant gathering for leaders in the field of immunotherapy.

Details of the Presentation

During this event, Coherus will present an abstract titled, CHS-114: An anti-CCR8 cytolytic monoclonal antibody demonstrates selective intratumoral Treg depletion and favorable immune remodeling in participants with advanced solid tumors. This research highlights promising results regarding the efficacy of CHS-114 in improving treatment outcomes for patients with hard-to-treat tumors.

Presentation Schedule

The presentation is set for Saturday, November 8, 2025, at the Prince George ABC Exhibit Halls, Gaylord National Resort and Convention Center. This platform will allow researchers and clinicians to engage with the findings and explore the implications for future cancer therapies.

Webinar Series Featuring Novel Therapeutics

In addition to the poster presentation, Coherus is part of the webinar series titled Targets for Cancer IO: A Deep Dive. The next session, focusing on the Development of Anti-CCR8 Ab - Mechanisms and Clinical Results, will occur on October 22, 2025, from 12:00 to 2:00 PM Eastern Time. This webinar is a fantastic opportunity for professionals to dive deep into the role of the C-C chemokine receptor 8 (CCR8) in immunological responses.

Webinar Insights

The webinar will be moderated by Enrico Lugli, PhD, from the Humanitas Research Hospital, and Rahul Roychoudhuri, MD, PhD, from the University of Cambridge. Guest faculty includes Rosh Dias, MD, MRCP, and Varun Kapoor, PhD, from Coherus Oncology, as well as Jo Van Ginderachter, PhD, from Vrije Universiteit Brussel. This lineup represents a formidable collection of expertise aimed at advancing cancer treatment.

About Coherus Oncology

Coherus Oncology stands out as a leading commercial-stage biotechnology company, particularly known for its innovative PD-1 inhibitor, LOQTORZI (toripalimab-tpzi). The company not only boasts impressive revenues but also maintains a robust pipeline of treatments currently in mid-stage clinical trials targeting various cancer types, including liver, lung, head and neck, and colorectal cancers.

Innovative Pipeline Development

Central to Coherus' commitment is its immuno-oncology pipeline, which focuses on advanced antibody therapies designed to enhance both innate and adaptive immune responses. One notable candidate, Casdozokitug, is an IL-27 antagonistic antibody now undergoing evaluation in several Phase 1/2 and Phase 2 studies for patients grappling with advanced solid tumors.

Ongoing Clinical Trials and Research

Moreover, CHS-114, the antibody being presented at SITC, is currently in Phase 1b/2a studies across a spectrum of advanced solid tumors. These trials have taken aim at malignancies that typically present substantial treatment challenges, including head and neck, colorectal, gastric, and esophageal cancers.

Contact Coherus Oncology

For investors and interested parties, Coherus encourages further engagement. Please contact Jodi Sievers, VP of Investor Relations & Corporate Communications, at: IR@coherus.com for more detailed information.

Frequently Asked Questions

What is the significance of the SITC meeting?

The SITC meeting showcases groundbreaking research and developments in cancer immunotherapy, offering a platform for experts to discuss advancements.

When is Coherus' poster presentation scheduled?

The presentation is scheduled for November 8, 2025, at the Prince George ABC Exhibit Halls.

What is CHS-114?

CHS-114 is an anti-CCR8 monoclonal antibody aimed at enhancing treatment responses in patients with advanced solid tumors.

How can one register for the webinar?

Details to register for the webinar series are available on the SITC website.

What types of cancers are part of Coherus' research?

Coherus' research encompasses various cancers, including liver, lung, head and neck, colorectal, gastric, and esophageal cancers.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 501

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 130

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 564

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 707

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 445

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 270

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 299

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 112

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 496

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading